NINLARO
Total Payments
$71.9M
Transactions
38,610
Doctors
9,213
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.0M | 4,496 | 2,710 |
| 2023 | $10.6M | 4,563 | 2,570 |
| 2022 | $17.6M | 4,385 | 2,207 |
| 2021 | $7.3M | 2,299 | 1,166 |
| 2020 | $6.4M | 1,234 | 573 |
| 2019 | $7.9M | 4,461 | 1,917 |
| 2018 | $9.3M | 8,752 | 3,050 |
| 2017 | $10.8M | 8,420 | 2,909 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $58.4M | 1,875 | 81.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.5M | 2,140 | 10.4% |
| Consulting Fee | $3.0M | 738 | 4.1% |
| Travel and Lodging | $1.3M | 3,082 | 1.9% |
| Food and Beverage | $868,862 | 30,368 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $792,438 | 328 | 1.1% |
| Royalty or License | $17,500 | 1 | 0.0% |
| Education | $2,216 | 77 | 0.0% |
| Charitable Contribution | $602.59 | 1 | 0.0% |
Payments by Type
Research
$58.4M
1,875 transactions
General
$13.5M
36,735 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MYDRUG: MYELOMA-DEVELOPING REGIMENS USING GENOMICS (GENOMICS GUIDED MULTI-ARM TRIAL OF TARGETED AGENTS ALONE OR IN COMBINATION WITH A BACKBONE REGIMEN) | Takeda Pharmaceuticals U.S.A., Inc. | $4.5M | 0 |
| A TACL PHASE 1/2 STUDY OF PO IXAZOMIB IN COMBINATION WITH VXLD CHEMOTHERAPY FOR CHILDHOOD RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA | Takeda Pharmaceuticals U.S.A., Inc. | $3.3M | 0 |
| A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $3.1M | 0 |
| AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) | Takeda Pharmaceuticals U.S.A., Inc. | $2.9M | 0 |
| PHASE 2 TRIAL OF MLN9708 (IXAZOMIB) COMBINATIONS IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MC1181) | Takeda Pharmaceuticals U.S.A., Inc. | $2.0M | 0 |
| X16117: PHASE I/II STUDY OF TWICE-WEEKLY IXAZOMIB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $1.9M | 0 |
| X16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA | Takeda Pharmaceuticals U.S.A., Inc. | $1.6M | 0 |
| A PHASE II WINDOW STUDY OF MLN9708 IN UNTREATED B-NHL | Takeda Pharmaceuticals U.S.A., Inc. | $1.4M | 0 |
| A PHASE 2, OPEN LABEL, RANDOMIZED TRIAL EVALUATING IXAZOMIB COMPARED TO IXAZOMIB-LENALIDOMIDE COMBINATION MAINTENANCE THERAPY FOR FRONTLINE MULTIPLE MYELOMA PATIENTS | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 1 |
| X16104: A Phase II Study of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 0 |
| A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | Millennium Pharmaceuticals, Inc. | $1.3M | 0 |
| A PHASE 2, OPEN-LABEL STUDY OF IXAZOMIB+DARATUMUMAB+DEXAMETHASONE (IDD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 0 |
| CCR-EMORY-IXA-001: A Randomized Phase II Study of DaRatumumab, Ixazomib, and Dexamethasone vs Daratumumab, bortezomib (VElcade) and dexamethasone followed by Daratumumab-Ixazomib-Dexamethasone in Newly Diagnosed Multiple Myeloma (DeRIVE study) | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 0 |
| A PHASE I/II STUDY OF IXAZOMIB AND IBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA | Takeda Pharmaceuticals U.S.A., Inc. | $1.2M | 0 |
| A TACL Phase 1/2 Study of PO Ixazomib in Combination with VXLD Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | Takeda Pharmaceuticals U.S.A., Inc. | $1.2M | 0 |
| X16117: Phase I/II Study of Twice-Weekly Ixazomib in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $1.1M | 0 |
| A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | Takeda Pharmaceuticals U.S.A., Inc. | $1.0M | 0 |
| X16094: Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma. | Takeda Pharmaceuticals U.S.A., Inc. | $869,877 | 0 |
| Phase II trial of IXAZOMIB and Dexamethasone versus IXAZOMIB, Dexamethasone and Lenalidomide, Randomized with NFKB2 rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) | Takeda Pharmaceuticals U.S.A., Inc. | $868,002 | 0 |
| PHASE II TRIAL OF IXAZOMIB AND DEXAMETHASONE VERSUS IXAZOMIB, DEXAMETHASONE AND LENALIDOMIDE, RANDOMIZED WITH NFKB2 REARRANGEMENT. (PROTEASOME INHIBITOR NFKB2 REARRANGEMENT DRIVEN TRIAL, PINR) | Takeda Pharmaceuticals U.S.A., Inc. | $855,334 | 0 |
Top Doctors Receiving Payments for NINLARO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $59.6M | 2,252 |
| , M.D | Medical Oncology | Spokane, WA | $630,465 | 412 |
| , MD | Hematology | Hackensack, NJ | $345,169 | 232 |
| , M.D | Medical Oncology | Salt Lake City, UT | $307,900 | 240 |
| , D.O | Hematology & Oncology | Greenville, SC | $294,684 | 210 |
| , M.D | Specialist | West Hollywood, CA | $285,714 | 195 |
| , M.D | Specialist | New York, NY | $256,191 | 149 |
| , MD | Medical Oncology | Dallas, TX | $215,188 | 145 |
| Saulius Girnius | Hematology & Oncology | Cincinnati, OH | $205,945 | 135 |
| , M.D | Hematology & Oncology | Washington, DC | $195,302 | 107 |
| , MD | Internal Medicine | Seattle, WA | $193,159 | 154 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $152,321 | 106 |
| , MD | Hematology & Oncology | Milwaukee, WI | $152,026 | 56 |
| , MD | Medical Oncology | Baton Rouge, LA | $150,934 | 136 |
| , M.D | Hematology & Oncology | Chandler, AZ | $148,419 | 107 |
| , M.D | Hematology & Oncology | Berkeley, CA | $138,938 | 114 |
| , MD | Hematology & Oncology | San Antonio, TX | $138,111 | 97 |
| , M.D | Hematology & Oncology | Miami, FL | $131,569 | 121 |
| , M.D. , M.P.H | Hematology & Oncology | Albany, NY | $122,908 | 84 |
| , M.D., PH. D | Hematology | Columbus, GA | $117,141 | 94 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $111,158 | 98 |
| , M.D | Medical Oncology | Hackensack, NJ | $108,910 | 67 |
| , MD | Hematology & Oncology | Denver, CO | $102,617 | 46 |
| , M.D | Specialist | Owing Mills, MD | $102,182 | 84 |
| , MD | Internal Medicine | New York, NY | $99,009 | 71 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $71.9M
- Total Doctors 9,213
- Transactions 38,610
About NINLARO
NINLARO is a drug associated with $71.9M in payments to 9,213 healthcare providers, recorded across 38,610 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $2.0M was paid across 4,496 transactions to 2,710 doctors.
The most common payment nature for NINLARO is "Unspecified" ($58.4M, 81.2% of total).
NINLARO is associated with 20 research studies, including "MYDRUG: MYELOMA-DEVELOPING REGIMENS USING GENOMICS (GENOMICS GUIDED MULTI-ARM TRIAL OF TARGETED AGENTS ALONE OR IN COMBINATION WITH A BACKBONE REGIMEN)" ($4.5M).